Cara Therapeutics

Youtube Subscribe

Open: 3.45 Close: 3.24 Change: -0.21

How to get informed about Cara Therapeutics Company Inc quickly using an AI.

The game is changing. There is a new strategy to evaluate Cara Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Cara Therapeutics are: Cara, Therapeutics, NASDAQCARA, announce, earnings, quarter, May, …

Concept Map

Semantic Network

Stock Summary

Cara Therapeutics, Inc. focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the.

Today's Summary

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs) State Street Corp boosted its position in CaraTherapeutics by 16.3% during second quarter.

Today's News

Cara Therapeutics (NASDAQ:CARA) recently announced its earnings for the quarter ending in May 2023. Cara has a 12-month low of $2.94 and a 12 month high of $12.98. Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs) Cara Therapeutics Inc. (Cara) options chain - yahoo finance. cara therapeutics, inc. (cara) Options chain - Yahoo Finance. Cara Therapeutics ( NASDAQ:CARA – Get Rating ) last announced its earnings results on Monday, May 15th. The firms 50-day moving average is $3.76 and its 200-day move is $7.39. State Street Corp boosted its position in CaraTherapeutics by 16.3% during second quarter.

Stock Profile

"Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut."

Keywords

Are looking for the most relevant information about Cara Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Cara Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Cara Therapeutics are: Cara, Therapeutics, NASDAQCARA, announce, earnings, quarter, May, and the most common words in the summary are: therapeutic, pharmaceutical, state, united, cara, pharma, biotechnology, . One of the sentences in the summary was: Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs) State Street Corp boosted its position in CaraTherapeutics by 16.3% during second quarter.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #state #united #cara #pharma #biotechnology.

Read more →

Youtube Subscribe

---